A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer.

International Journal of Clinical Oncology
Kohei ShitaraKei Muro

Abstract

Based on the results of the SPIRITS trial, combination chemotherapy of S-1 plus cisplatin (SP) is now considered the standard treatment for patients with advanced gastric cancer (AGC) in Japan. On the other hand, several non-Japanese studies have shown the efficacy of capecitabine plus cisplatin (XP), which has been used as the reference arm in recent global studies of AGC. We retrospectively compared the efficacy and safety of SP and XP in first-line treatment for patients with AGC. From August 2006 to November 2008, 26 AGC patients received XP in the context of 2 global trials (AVAGAST and ToGA), and 50 patients received SP during the same period. The objective response rate was 43.2 % in the SP group and 50 % in the XP group, with no significant difference (p = 0.62). There were also no significant differences in progression-free survival (median 5.8 vs. 5.2 months; p = 0.91) and overall survival (median 13.8 vs. 13.5 months; p = 0.97) between the SP and XP groups. The frequencies of hematological toxicities of grade 3 or more and non-hematological toxicities were not significantly different between the 2 groups. Although grade 1 or 2 hand-foot syndrome was more common in the XP group, no patients experienced grade 3 or more...Continue Reading

References

Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Y SakataT Taguchi
Apr 20, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rudolf NapieralskiGisela Keller
Sep 8, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaffer A AjaniPeter Urrea
Jan 24, 2006·Anti-cancer Drugs·Junichi SakamotoUNKNOWN Clinical Study Group of Capecitabine
Sep 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neal J MeropolRoland Schwarting
Nov 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemUNKNOWN V325 Study Group
Jan 4, 2008·The New England Journal of Medicine·David CunninghamUNKNOWN Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom
Jan 21, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y-K KangP I McCloud
Oct 13, 2009·The Lancet Oncology·Narikazu BokuUNKNOWN Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaffer A AjaniSilvia Falcon
Aug 17, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Atsushi OhtsuYoon-Koo Kang

❮ Previous
Next ❯

Citations

Mar 1, 2012·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Kohei ShitaraKei Muro
Apr 22, 2015·World Journal of Gastroenterology : WJG·An-Bing HeYan Tang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.